All Type of News
Weakened growth rates of leading PPI inhibitors; domestic ones making advances
Although the growth rates of leading proton pump inhibitors(PPI) have been weakened, their domestic drugs seem to make an advance.
According to the UBIST data of the third quarter of 2015 on the 11th, 9 of the top 15...
Korean stem cell treatment technology acquired approval in Japan for the first time
R-Japan Co., Ltd., a Japanese affiliated company of Nature Cell, announced on the 11th that Nishihara Medical Clinic acquired approval of stem cell treatment for critical limb ischemia diseases, which includes Burger’...
Will newly-joined domestic pharmaceutical companies be successful in DPP-4 diabetic treatment market?
The DPP-4 inhibitor diabetes treatment market, which has been occupied by Januvia and Trajenta, has recently been invaded by domestic pharmaceutical companies.
Handok has made progress in commercializing ambitiously ...
PMS expiration of Twynsta on August next year
‘Twynsta(telmisasrtan-amlodipine),’ the top sales hypertension treatment, has active competition ahead for the same substance drug due to expiration of post-marketing surveillance(PMS) on August next year.
A number o...
“Let’s increase effectiveness of antismoking treatment by health insurance benefit”
In order to maximize the antismoking effect caused by the tobacco price raise, an argument has been raised that provision of the health insurance benefit must be enforced to actively encourage private medical institut...
Syrup and contrast medium are about to be eradicated from the market
The pharmaceutical industry has raised a voice of concern regarding pharmaceutical products such as syrup and contrast medium, which will be excluded from the object of protection by the provision organization of low-...
Which company will acquire ‘Mercilon’ this November?
The whereabouts of ‘Mercilon,’ a Bayer’s oral contraceptive, which will be decided within this month, has attracted attention.
As pointed out for the Substantial Lessening of Competition by the Fair Trade Commission(...
Hanmi Pharm signed an license agreement of new bio-drug with JanssenHanmi Pharm(CEO Kwan-soon Lee) announced a license agreement to develop and commercialize HM12525A (LAPSGLP/GCG), a self-developed oxyntomodulin-based diabetes and obesity treat...
|
Hanmi Pharm closer to Celltrion in market capitalizationHanmi Pharm has exceeded KRW 8 trillion in market capitalization from a series of technology exports.
It has gotten closer by KRW 200 billion to the leading market capitalizati...
|
MOHW to agree on establishment of National Medical University
While the Ministry of Health and Welfare(MOHW) has suddenly changed its position to agreeing establishment of the national medical school, the office of the National Assembly’s Health and Welfare Committee and its rel...
